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Abstract
Several countries have systems in place to support the managed entry of new health technologies. The big challenge
for these so-called horizon-scanning systems is to select those technologies that require decision support by means of an
early evaluation. Clinical experts are considered a valuable source of information on new health technologies, but research
on the relevance of their input is scarce. In 2000, we asked six Danish expert oncologists to predict whether a sample of 19
new anticancer drugs would impact Danish health care over the next 5 years. In 2005, we assessed the accuracy of these
predictions in a delayed type cross-sectional study. The speciﬁcity of the Danish experts’ prediction was 1 (95% conﬁdence
interval 0.74–1.00) and the sensitivity was 0.63 (0.31–0.86). The negative predictive value was 0.79 (0.52–0.92) and the
positive predictive value was 1 (0.57–1.00). This indicates that clinical experts have the ability to predict which new
anticancer drugs are unlikely to have an impact. This information can be used to increase the efﬁciency of selecting new
technologies for evaluation. As the experts missed 37% of drugs that are in need of guidance, they should not be relied
upon to select drugs relevant for evaluation.
r 2006 Elsevier Ltd. All rights reserved.
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Introduction
Several countries have systems in place to support
the managed entry of new health technologies. The
big challenge for these so-called horizon-scanning
systems (HSS) is to select those technologies that
require decision support by means of an early
evaluation of their potential impact. By deﬁnition
this pertains to new technologies that, when
introduced in health care, will be most in need of
public planning and regulation to promote or
discourage diffusion (Gelijns, Brown, Magnell,
Ronchi, & Moskowitz, 2005). Clinical experts are
considered a valuable source of information on new
health technologies (Robert, Stevens, & Gabbay,
1999), but research on the relevance of their input is
scarce. In horizon scanning, information sources to
inform on new health technologies are categorized
as primary, secondary, and tertiary, depending on
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the proximity to the invention. Clinical expertise is
considered a secondary source and can, according
to Robert et al. (1999), be used either for identiﬁca-
tion purposes or to ﬁlter information from other
sources. ‘Filtering’ is essentially a ﬁrst selection of
identiﬁed technologies, resulting in a narrowing
down of the potential number of technologies to
evaluate. Filtering is recognized by HSSs and their
network, EuroScan (EuroScan, 2006) as an indivi-
dual step in the process of identifying and evalua-
ting signiﬁcant health technologies. Most HSSs des-
cribe it as an implicit process (Douw & Vondeling,
2006). In some systems, ﬁltering is based on experts’
predictions of the impact of new health technologies
on the health care system. With this paper we
intend to contribute to the further development of
ﬁltering mechanisms by analysing the accuracy
of predictions by Danish expert oncologists in
2000 on newly identiﬁed anticancer drugs. The
predictions were sought as part of a preparatory
study on a Danish HSS and aimed to support a
ﬁrst selection of technologies for early evalua-
tion (Douw, Vondeling, Sørensen, Jørgensen, &
Sigmund, 2004).
Methods
The predictions of clinical experts were assessed
as a diagnostic tool in a diagnostic accuracy study.
The study is a ‘‘delayed type cross-sectional study’’,
because the reference standard was not applied at
the same time as the index test. Instead the drugs
were followed up during a suitable predeﬁned
period (Knottnerus & Muris, 2003), in the case of
HSSs a ﬁve-year period (Robert et al., 1999). The
sample included 19 anticancer drugs in treatment of
breast, lung, colorectal, and skin cancer, to be
administered by clinicians in hospitals. It was part
of a larger sample obtained in 2000 by a postal
survey to collect newly identiﬁed health technologies
at all HSSs involved in EuroScan.
The index test involved the predictions of 6
clinical oncologists of the impact of the 19 anti-
cancer drugs. The oncologists were pointed out as
experts by senior executives and managers repre-
senting stakeholders in Danish health care (Douw
et al., 2004). All experts were in senior managing
positions, and active in research and clinical practice
at 5 of 6 specialized oncology centres in Denmark
(Aalborg, Aarhus, Herlev, Odense and Vejle hospi-
tal and Rigs hospital in Copenhagen). We asked the
experts to predict which drugs would be new for
Denmark and be introduced within 0–5 years. We
furthermore asked them to ﬁll out for 4 types of
impact (i.e. clinical, ﬁnancial, organisational, social
and/or ethical) whether a small, big or no impact
could be expected. The experts could select more
than one type of impact. For example, an expert
could ﬁll out that a drug would have a big ﬁnancial
impact, a small clinical impact, a small organisa-
tional impact, and no social impact (Douw et al.,
2004). An anticancer drug was considered for
further evaluation if a majority of the experts
judged it to be new, expected it to be introduced
within 5 years, and to have at least one type of big
impact.
The reference standard to establish the ﬁnal
diagnosis of impact reﬂects the need for decision
making on the drug. A drug’s impact was con-
sidered to be predicted correctly by the experts when
either a positive or negative decision was made by
the Cancer Steering Group (CSG), a national
committee installed by the Health Minister in 1998
to supervise the improvement of cancer diagnostics
and treatment, or if actual use was documented in at
least one of the 6 oncology centres in Denmark in
the period 2000–2005. Use was considered as a
proxy for an investment decision by hospitals as
well, because of the typically high costs of new
anticancer drugs (Apolone, Joppi, Bertele, &
Garattini, 2005). We documented use with a postal
survey among all 6 oncology centres, carried out in
June 2005.
Data were analysed on the basis of Altman’s
statistical package using the recommended Wilson’s
method for conﬁdence intervals (Altman, Machin,
Bryant, & Gardner, 2000).
Results
Table 1 shows that a majority of experts predicted
ﬁve cases to have an impact on Danish health care.
In all these cases exclusively a big ﬁnancial impact
was predicted. In only one of the ﬁve cases a
decision was made by the CSG, but all ﬁve drugs
were introduced in clinical practice in at least one of
the six Danish oncology centres in the period
2000–2005. A minority of experts predicted twelve
of the drugs (63%) to have a big clinical impact, 13
drugs (68%) to have a big organisational impact,
and 6 drugs to have a big social/ethical impact.
In the cases of Geﬁnitib, Capecitabine and Tegafur
Uracil the experts did not correctly anticipate
the future.
ARTICLE IN PRESS
K. Douw, H. Vondeling / Social Science & Medicine 64 (2007) 283–286284
Au
th
or
's 
  p
er
so
na
l   
co
py
The prevalence of drugs in the sample that was in
need of decision making was 42% (8 out of 19).
Table 2 shows the correspondence between the
index test and the reference standard. The index
test, i.e. the experts’ predictions of the impact of the
new anticancer drugs, had a sensitivity of 0.63 (95%
conﬁdence interval 0.31–0.86). The speciﬁcity of the
test was 1 (0.74–1.00). The negative predictive value
was 0.79 (0.52–0.92) and the positive predictive
value was 1 (0.57–1.00).
Discussion
The analysis indicates that the experts have the
ability to predict which technologies are unlikely to
have an impact on the health care system. Their
predictions are therefore useful in informing which
drugs should not be selected for evaluation. We do
not advocate relying on experts’ predictions to
indicate which anticancer drugs will truly have an
impact, since they missed 37% of the drugs that
were in need of decision making (sensitivity ¼ 0.63).
A PPV of 1 looks like a rather good result for a test
but this is inﬂuenced by a high prevalence (42%) of
drugs that are in need of guidance, which goes
together with a high probability to encounter such
cases by chance. For the 5 anticancer drugs in our
sample that were judged to have an impact, always a
ﬁnancial impact was predicted. This is not surpris-
ing given the typically high costs of new anticancer
drugs (Apolone et al., 2005). Eight of the 11 drugs
correctly predicted by the Danish experts not to
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Table 1
Prediction of impact of 19 anticancer drugs, launch in Denmark, and outcomes for the reference standard
Drug Indication Launch in DKa Index test Reference standard
Predicted in 2000
to have an
impact
Decision by
Cancer Steering
Group
(2000–2005)
Documented use
in at least one of
the 6 Danish
oncology centres
(2000–2005)
Paclitaxel Breast cancer X (2004) X — X
Docetaxel Breast cancer X (2000) — — —
Trastuzumab Breast cancer X (2000) X — X
Goserelin Early breast cancer X (1999) — — —
Raloxifene Prevention of breast cancer — — — —
Docetaxel Non-small cell lung cancer X (2000) X — X
Paclitaxel Non-small cell lung cancer X (2003) — — —
JM 216 Lung cancer — — — —
Tirapazimine Lung cancer — — — —
Geﬁnitib Lung cancer — — X —
Irinotecan Colorectal cancer X (1999) X — X
Oxaliplatin Colorectal cancer — X X X
Capecitabine Colorectal cancer X (2001) — — X
Eniluracil Colorectal cancer — — — —
Tegafur uracil Colorectal cancer X (2001) — — X
Edreclomab Colorectal cancer (adjuvant to
current regimen)
— — — —
OncoVAX-CL Colorectal cancer (post surgical
treatment–stage II and III)
— — — —
Antigastrin-17 Reduce precancerous proliferation — — — —
Melanoma
Vaccine
(Oncophage)
Metastatic malignant melanoma — — — —
aIndicates whether a drug reached the Danish market and the launch date.
Table 2
Experts’ prediction with reference to the need for decision making
Experts’ majority vote on
likely impact
Need for decision on the drug
Yes No Total
Positive 5 0 5
Negative 3 11 14
Total 8 11 19
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have an impact, never reached the market, and
would therefore never have made an impact. Three
out of 14 drugs are incorrectly labelled as not being
in need of decision making. This can be interpreted
as a failed alarm of 21% (1-NPV), and is tolerable
as drugs predicted not to have an impact will be
monitored.
Simpson, Hyde, Cook, Packer, & Stevens (2004)
conclude in a comparable analysis that for the
English and Welsh context sensitivity is the most
important result, in order not to miss any poten-
tially signiﬁcant technologies, that otherwise would
enter the health care system without evaluation. As
the outcome of this HSS’s selection process feeds
into the topic selection process for a national
guidance programme (NICE) this conclusion is
understandable, but for the Danish context a
high sensitivity is not the key, as experts’ informa-
tion is just a ﬁrst step in the selection, which will
be followed by a criteria-based priority-setting
procedure.
In this study the index test, as well as the
reference test need to be discussed. Regarding the
index test, the selection of experts and the way they
were accessed are important issues. We asked
stakeholders to select opinion leaders in the area
of oncology (Douw et al., 2004), as in general these
are considered to have appropriate domain knowl-
edge. However, it is unclear what exactly constitutes
expertise in relation to forecasting the impact of new
anticancer drugs, and more research into which
experts to select would therefore be needed. In this
study we used a single round to elicit opinions, and
used a decision rule (a majority vote of ‘positive’
answers on novelty, time horizon, and impact of the
technology) to interpret the answers of the experts,
as there was never unanimity on all the answering
options. If not a majority vote would be applied
than 89% of the anticancer drugs would be judged
to have an impact. The sensitivity of the test would
then be 1.00, and speciﬁcity 0.18, resulting in a high
number of false positives, which would not serve
ﬁltering purposes very well. There is evidence that
several rounds, as used in consensus methods such
as the Delphi method or the nominal group
technique (NGT), improve the accuracy of a
prediction (Armstrong, 2001). These methods could
also shed more light on the rationale for the
answers, as experts can provide arguments for their
estimates when confronted with feedback from the
other experts. The value of both methods as
forecasting tools is, however, not uncontested
(Armstrong, 2001), therefore there is a need for
studies comparing different alternatives to elicit
expert opinion on the impact of new health
technologies. In any method it is recommendable
to match the results to observable events (Jones &
Hunter, 1995), as was done in this study.
Although the true value of clinical experts’
predictions needs to be established by future studies
with bigger samples and in other clinical specialties
as well, this study indicates that experts’ informa-
tion may be valuable as part of a process aimed at
efﬁciently selecting technologies for evaluation.
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